Filing summary
Registrant: The filing identifies GlycoMimetics, Inc., not Crescent BioPharma, Inc. It is a Form 10-Q for the quarter ended September 30, 2014, filed October 31, 2014. The financial statements are unaudited.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates and has no products available for sale. Its lead candidate, rivipansel, is licensed to Pfizer; the company retains rights to its other candidates. Results cover the three and nine months ended September 30, 2014, compared with the same 2013 periods.
Key financial metrics
| Metric | 2014 | Comparable period |
|---|---|---|
| Revenue, third quarter | $0 | $52,571 in Q3 2013 |
| Revenue, nine months | $15.03 million | $3.92 million in 2013 |
| Net loss, third quarter | $6.62 million | $3.70 million in Q3 2013 |
| Net loss, nine months | $3.73 million | $6.74 million in 2013 |
| R&D expense, nine months | $14.29 million | $8.58 million in 2013 |
| Cash and cash equivalents, September 30 | $61.36 million | $2.31 million at December 31, 2013 |
| Operating cash flow, nine months | $1.87 million provided | $9.97 million used in 2013 |
| Total liabilities, September 30 | $4.72 million | $2.38 million at December 31, 2013 |
There were no product sales; the nine-month 2014 revenue primarily reflects a $15 million Pfizer milestone payment. Profit margins are not meaningful for this development-stage, loss-making business. The balance sheet lists no borrowings; it does not report a separate debt total. Current assets were $61.95 million versus current liabilities of $4.71 million.
Changes versus prior period
- Third-quarter operating loss widened to $6.70 million from $3.70 million, mainly as costs and expenses rose to $6.70 million from $3.75 million.
- Nine-month operating loss narrowed to $3.74 million from $6.74 million, primarily because revenue included Pfizer’s $15 million milestone payment; operating expenses also increased by $8.11 million.
- R&D expense rose 67% for the nine months, reflecting GMI-1271 manufacturing and development, its AML Phase 1 trial, and a $1.5 million amount accrued to the University of Basel. General and administrative expense rose 116%, in part due to IPO and public-company costs and higher stock compensation.
- Cash increased substantially following the January 2014 IPO, which generated $57.2 million net proceeds, and the Pfizer payment. Preferred shares converted into common stock at the IPO; outstanding common shares were 18.89 million at September 30.
Outlook, risks and notable items
- Management expected available cash to fund operations and capital expenditures for at least 12 months from September 30, 2014, excluding possible future Pfizer milestones. The company expected operating losses and negative operating cash flow over the longer term and may need additional financing.
- Pfizer reported a manufacturing development issue affecting formulated rivipansel supply, significantly delaying Phase 3 initiation. The remaining $20 million of the scheduled $35 million Phase 3 milestone depends on first-patient dosing; its timing and receipt are uncertain.
- GMI-1271’s healthy-volunteer Phase 1 dosing was completed in July 2014, with final data expected by year-end. The company planned a Phase 1/2 AML trial and expected a University of Michigan GMI-1271 VTE study to begin in Q4 2014.
- The company reported an eight-year lease for future Rockville headquarters, expected to commence November 1, 2015, with annual base rent of $607,500, subject to escalation. Total operating lease obligations reported were $5.85 million.
- Key risks include clinical and regulatory failure, manufacturing and supply delays, dependence on Pfizer and third-party manufacturers, future financing needs and dilution, competition, and uncertainty of eventual profitability. The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Confirm the intended company: the request names Crescent BioPharma, but this filing is for GlycoMimetics, Inc.
- Check subsequent disclosures on the cause and resolution of the rivipansel manufacturing issue, Phase 3 timing, and the remaining $20 million milestone.
- Review GMI-1271 trial results and whether the planned AML and VTE studies commenced as anticipated.
- Assess cash use, financing needs, lease commitments, and share dilution against the company’s stated runway; the 12-month runway is management’s estimate, not a guarantee.